Article: 

Lancet Respir Med. 2023 Apr;11(4):329-340.

“Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials”

Reviewer: Dr. Paola Orozco